Last reviewed · How we verify

Primaxin — Competitive Intelligence Brief

Primaxin (CILASTATIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Renal Dehydropeptidase Inhibitor. Area: Metabolic.

marketed Renal Dehydropeptidase Inhibitor Dipeptidase 1 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Primaxin (CILASTATIN) — Merck & Co.. Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Primaxin TARGET CILASTATIN Merck & Co. marketed Renal Dehydropeptidase Inhibitor Dipeptidase 1 1985-01-01
Recarbrio RELEBACTAM Merck & Co. marketed Renal Dehydropeptidase Inhibitor [EPC] 2019-01-01
IMIPENEM ANHYDROUS IMIPENEM ANHYDROUS marketed Renal Dehydropeptidase Inhibitor [EPC] 1985-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Renal Dehydropeptidase Inhibitor class)

  1. Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Primaxin — Competitive Intelligence Brief. https://druglandscape.com/ci/cilastatin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: